A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2001
11/13/2001	US6316002 Germination activated red Ganoderma lucidum spores and method for producing the same
11/13/2001	US6315979 Administering to an animal in vivo in an implantable catheter radioiodinated phenol derivative for brachytherapy
11/13/2001	US6315978 Bioconjugates and delivery of bioactive agents
11/13/2001	CA2171728C Triaryl-ethylene derivatives for use in therapy
11/08/2001	WO2001083782A2 Novel proteases
11/08/2001	WO2001083781A2 14094, a novel human trypsin family member and uses thereof
11/08/2001	WO2001083775A2 Proteases
11/08/2001	WO2001083774A2 Novel mutated form of arginine deiminase
11/08/2001	WO2001083755A2 Human anti-cd40 antibodies and methods of making and using same
11/08/2001	WO2001083750A2 Dendritic cell co-stimulator molecules
11/08/2001	WO2001083740A2 Splice-region antisense composition and method
11/08/2001	WO2001083724A1 A new polypeptide - human dihydrooratase 17 and the polynucleotide encoding it
11/08/2001	WO2001083719A2 25692, a novel human o-methyltransferase family member and uses thereof
11/08/2001	WO2001083698A2 Compositions and methods for inducing activation of dendritic cells
11/08/2001	WO2001083689A2 PEPTIDES FROM FRAMESHIFT MUTATED DNA POLYMERASE δ GENE
11/08/2001	WO2001083687A2 A novel polypeptide, a human pax protein 23 and the polynucleotide encoding the polypeptide
11/08/2001	WO2001083562A2 Hybrid protein and vector encoding the same for inhibition of angiogenesis
11/08/2001	WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083548A1 Novel derivative of cell chemotactic factor
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083543A1 Human wingless-like gene
11/08/2001	WO2001083542A1 A novel polypeptide, human p18 protein 21 and the polynucleotide encoding said polypeptide
11/08/2001	WO2001083541A1 A novel polypeptide-human kruppel associated dna binding protein 42 and the polynucleotide encoding said polypeptide
11/08/2001	WO2001083540A1 A novel polypeptide-kiaa0883-44 and the polynucleotide encoding said polypeptide
11/08/2001	WO2001083536A1 A novel polypeptide-cytokine receptor 15 and the polynucleotide encoding said polypeptide
11/08/2001	WO2001083525A2 Modified peptides, comprising an fc domain, as therapeutic agents
11/08/2001	WO2001083524A2 Rna metabolism proteins
11/08/2001	WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083508A1 Antisense modulation of zinc finger protein-217 expression
11/08/2001	WO2001083496A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
11/08/2001	WO2001083481A1 Imidazopyridine derivatives
11/08/2001	WO2001083477A1 Stolonoxides
11/08/2001	WO2001083475A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	WO2001083469A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001	WO2001083457A2 Benzimidazole-2-carbamates and their use in cancer treatment
11/08/2001	WO2001083456A1 Condensed heteroaryl derivatives
11/08/2001	WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001	WO2001083438A2 New gamma selective retinoids
11/08/2001	WO2001083436A2 Small technetium-99m and rhenium labeled agents and methods for imaging tumors
11/08/2001	WO2001083427A1 PPARη MODULATORS
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001083385A2 Devices and method for production of traceable immunizing drinking water, other liquids and gas
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082969A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
11/08/2001	WO2001082968A1 Cell proliferation inhibitors
11/08/2001	WO2001082963A2 Method of identifying and producing antigen peptides and use thereof as vaccines
11/08/2001	WO2001082961A2 Methods for treating bone tumors
11/08/2001	WO2001082959A1 Omp protein associated with autologous and/or heterologous tumour cell lysate
11/08/2001	WO2001082958A2 Methods of producing membrane vesicles
11/08/2001	WO2001082955A1 Depletion method of blood plasma ascorbate
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082949A2 Method of reducing side effects of chemotherapy in cancer patients
11/08/2001	WO2001082948A2 Uses of tgap7 for the modulation of leucocyte activation
11/08/2001	WO2001082935A1 Remedies for cancer
11/08/2001	WO2001082923A1 Estrogen receptor modulators
11/08/2001	WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001	WO2001082910A2 Combination of progesterone and mifepristone for cancer therapy
11/08/2001	WO2001082907A2 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
11/08/2001	WO2001082900A1 Non-invasive gene targeting to the brain
11/08/2001	WO2001082899A2 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082859A2 Method for producing r-teatrol analogs having an antineoplastic activity
11/08/2001	WO2001082699A1 A gene therapy system and method using alpha-msh and its derivatives
11/08/2001	WO2001068070A8 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001041801A3 Mutant simplex virus for treating unwanted hyperproliferative cell growth
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001040460A8 Screening method for compounds capable of modularing egr-1-regulated expression
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001036630A3 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001030765A3 Method for producing therapeutic agents for ulcers
11/08/2001	WO2001026680A3 Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
11/08/2001	WO2001018035A3 Muc-1 derived peptides
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2001002551A3 Virus like particles, preparation and use in screening and functional genomics
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000053745A9 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
11/08/2001	WO2000033888A3 Prodrug compounds and process for preparation thereof
11/08/2001	WO2000017133A3 Lta4 hydrolase inhibitors
11/08/2001	US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001	US20010039293 4((4-chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphathalene-2-carbonyl)-amino)-2,6-difluoro-benzoic acid or its esters or salts used as agonists of alpha-retinoid receptors (=raralpha)
11/08/2001	US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039273 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039270 Tin polyoxaalkanecarboxylates and compositions containing them
11/08/2001	US20010039017 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
11/08/2001	US20010039016 Measurement, calibration gene expression
11/08/2001	US20010038849 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/08/2001	US20010038842 Treating a disease characterized by expression of vascular endothelial growth factor-D (VEGF-D) by a tumor by screening for a VEGF-D expressing tumor, administering a VEGF-D antagonist to prevent binding of VEGF-D to its receptor
11/08/2001	US20010038841 Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
11/08/2001	US20010038830 N,O-amidomalonate platinum complexes
11/08/2001	EP1144348A3 Lta 4? hydrolase inhibitors
11/08/2001	DE10020935A1 Verwendung von Photofrin als Radiosensitizer Using Photofrin as a radiosensitizer

1 ... 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 ... 2211